Sangamo Therapeutics (SGMO): Ready To Start Accumulating Ahead Of A Pivotal 2023
Sangamo is making progress across their pipeline programs. Read more to see why I am willing to accumulate a hefty position in SGMO stock.
Stay updated with breaking news from Buy Threshold. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sangamo is making progress across their pipeline programs. Read more to see why I am willing to accumulate a hefty position in SGMO stock.
Collegium's new products from the BDSI acquisition have already helped it report record revenue. Read more to see my strategy to accumulate COLL stock.
Esperion Therapeutics reported its Q2 earnings that revealed a beat on revenue, but a miss on EPS. However, ESPR said it has hit 100% MACE-4 accumulation.
PacBio’s HiFi and SMRT sequencing technology continues to fuel growth. PACB believes itself to be on track to hit its full-year revenue guidance of ~$160-$170M. See why I rate PACB as a buy.